, Venture Investor, Morningside Technology Advisory, USA
Mr. Coleridge has served as the CEO of ViOptix, Inc for the past 5 years. A highly experienced medical technology executive, Mr. Coleridge’s recent experience includes serving as Co-Founder of Apple Medical (sold to Cooper Surgical), Executive Vice President, FEI Women’s Health (sold to Barr Laboratoriess, now Teva Pharmaceuticals), developer of the only non-hormonal female contraceptive, Mr. Coleridge has spent more than 20 years starting or being part of the senior management team for several early-stage life science companies, including Kingston Diagnostics, developer of the first whole blood cholesterol test (Licensed to Warner Lambert/Pfizer) and CEO of Synthon Chiragenics (sold to Avecia). After the sale of FEI to Barr Laboratories in 2005, Mr. Coleridge joined Morningside Technology Advisory, LLC. He is also a member of the Board of Directors of Excera Orthopedics and Humanzyme, Inc.
, Professor of Pediatrics (Neonatology), of Microbiology and Immunology, and, by courtesy, of Radiology and of Bionengineering, Standford University, USA
Dr. Contag is a Professor in the Departments of Pediatrics, Radiology, Bioengineering and Microbiology & Immunology at Stanford University, and a member of BioX Faculty for interdisciplinary sciences, and of the Immunology Faculty.
Dr. Contag received his B.S. in Biology from the University of Minnesota, St. Paul in 1982. He received his Ph.D. in Microbiology from the University of Minnesota, Minneapolis in 1988 where he did his dissertation research on the topic of viral infections of the central nervous system. He was a postdoctoral fellow at Stanford University from 1990-1994 in the Department of Microbiology where he studied mother-to-infant transmission of HIV, and then joined the faculty in Pediatrics at Stanford in 1995 with a joint appointment in Microbiology and Immunology and courtesy appointments in Radiology and Bioengineering. While studying viral diseases, Dr. Contag was inspired to create new imaging tools that would enable studying biology in living animals, and this lead to a series of new tools and technologies that have opened new windows into mammalian systems—these tools fundamentally changed the way we explore mammalian biology, and are used around the world by pharmaceutical companies, biotech companies and universities develop novel therapies.
Dr. Contag is the Associate Chief of Neonatal and Developmental Medicine, director of Stanford’s Center for Innovation in In Vivo Imaging (SCI3
) and co-director of the Molecular Imaging Program at Stanford (MIPS). Dr. Contag is a pioneer in the field of molecular imaging and is developing imaging approaches aimed at revealing molecular processes in living subjects, including humans, and advancing therapeutic strategies through imaging. His laboratory develops macroscopic and microscopic optical imaging tools and uses imaging to assess tissue responses to stress, reveal immune cell migration patterns, understand stem cell biology and advance biological therapies. He is a founding member and a past president of the Society for Molecular Imaging, and is a recipient of the Achievement Award from the Society for Molecular Imaging for his fundamental contributions to imaging. Dr. Contag is a Fellow of the World Molecular Imaging Society (WMIS) and currently President of WMIS. Dr. Contag was a founder of Xenogen Corp. (now part of Perkin Elmer) established to commercialize innovative imaging tools for biomedicine, and a founder of ConcentRx—a cancer therapy company.
Richard B. Dorshow
, Ph.D., Chief Scientific Officer, MediBeacon, Inc., USA
Richard B. Dorshow, Ph.D., Co-Founder, President, and Chief Scientific Officer of MediBeacon Inc., is a research physicist and technology manager with over 25 years in R&D focusing on business oriented research programs. He is author on over 70 technical articles, and is co-inventor on over 60 issued US patents. Dr. Dorshow recently had the unique opportunity to launch MediBeacon with the acquisition of the optical diagnostics technology developed under his leadership at a major pharmaceutical company. He is now guiding the company through its clinical program to commercialize optical agents for human disease detection and monitoring.
, PhD, Professor, Engineering Science, Dartmouth College, President, DoseOptics LLC
Brian W. Pogue, Ph.D. is Professor of Engineering, Physics & Astronomy, at Dartmouth College, and Adjunct Professor of Surgery at the Geisel School of Medicine. He has a doctoral degree in Medical Physics from McMaster University in Canada, and he has published over 250 peer-reviewed papers in optical imaging systems, with a focus on molecular and structural imaging of cancer for surgical guidance and imaging radiation therapy. He is a fellow of the Optical Society of America, serves on the editorial board of J. Biomed.Optics, Medical Physics, Physics in Medicine and Biology, and Breast Cancer Research. In 2015 he founded DoseOptics LLC to help translate Cerenkov light imaging, as a novel radiation therapy imaging technology to help therapists confirm dose delivery.
Daniel Schultz, MD, F.A.C.S.
, Principal, Medical Devices & Combination Products, GreenLeaf Health, LLC, USA
Dr. Daniel Schultz has devoted his 35-‐year career to supporting and advancing Americans’ public health. Named Director of FDA’s Center for Devices and Radiological Health in 2004, Dr. Schultz has led the development, implementation and evaluation of regulatory policies concerning medical devices and radiation emitting products for more than five years.
Dr. Schultz continues his commitment to public health at Greenleaf, where as Principal, Medical Devices and Combination Products, he provides strategic consulting services to bring innovative devices to patients. Dr. Schultz received his medical degree from the University of Pittsburgh and is Board-‐ certified in Surgery and Family Practice.
, Entrepreneur, USA
Eric Swanson is a director, advisor, and participant in a variety of industrial, academic, entrepreneurial, government, and non-profit activities. Mr. Swanson serves as a director for Acacia Communications, Curata Incorporated, and NinePoint Medical. He is also research affiliate at the Massachusetts Institute of Technology, consultant at Draper Laboratory, catalyst at the MIT Deshpande Center for Technological Innovation, and is editor of OCT News (www.octnews.org
). Mr. Swanson is a co-founder or founding board member of five companies which have evolved over time and collectively shipped far in excess of $1B in products around the world. He is a Fellow of the OSA and senior member of the IEEE, has authored ~195 technical papers and conference presentations, holds ~36 US patents, and co-authored 6 book chapters. In 2002, he was a co-recipient of the Rank Prize in Opto-Electronics for pioneering work in the field of optical coherence tomography. In 2012, he was a co-recipient of the Champalimaud Award also for pioneering work in the field of optical coherence tomography. Mr. Swanson holds a B.S. summa cum laude in Electrical Engineering from the University of Massachusetts at Amherst and an M.S. in Electrical Engineering from the Massachusetts Institute of Technology.
, Program Director, National Institute of Neurological Disorders and Stroke
Edmund (Ned) Talley is a Program Director at the National Institute of Neurological Disorders and Stroke, where he co-leads the group overseeing the NIH component of the BRAIN Initiative, a multi-US government agency effort initiated by President Obama. He is Project Officer for technology development in optical methods and optical probes for recording and modulating neural activity. In addition, he oversees portfolios of research projects focused on basic mechanisms of communication between neurons, high-risk/high-innovation grants, and research resources. Prior to joining NINDS, Dr. Talley studied contributions of ion channels to the dynamics of neural activity and modulation at the University of Virginia.